(GEHC) GE HealthCare Technologies - Ratings and Ratios

GE HealthCare Technologies Inc. is a leading global provider of medical technologies and digital solutions that enable healthcare providers to deliver high-quality patient care. The companys comprehensive portfolio spans multiple business segments, including Imaging, Advanced Visualization Solutions, Patient Care Solutions, and Pharmaceutical Diagnostics, catering to various medical needs such as diagnosis, treatment, and patient monitoring.

The companys Imaging segment is a significant player in the medical imaging landscape, offering a broad range of products and services, including molecular imaging, CT scanning, MR imaging, and X-ray systems. Meanwhile, its Advanced Visualization Solutions segment provides specialized solutions for clinical areas like womens health and cardiovascular care. Patient Care Solutions focuses on delivering innovative patient monitoring, diagnostic cardiology, and maternal infant care products, while Pharmaceutical Diagnostics supplies diagnostic agents and contrast media pharmaceuticals to the radiology and nuclear medicine industries.

With its headquarters in Chicago, Illinois, GE HealthCare Technologies Inc. operates on a global scale, serving customers in the United States, Canada, and internationally. The companys recent rebranding from GE Healthcare Holding LLC to GE HealthCare Technologies Inc. in December 2022 reflects its evolving identity and commitment to advancing healthcare technology.

Analyzing the , we observe that GEHCs last price is $71.16, slightly above its 20-day simple moving average (SMA) of $71.09, indicating a potential bullish trend. However, its 200-day SMA stands at $81.92, suggesting a longer-term downtrend. The average true range (ATR) of 2.32 represents a 3.25% daily price fluctuation, signaling moderate volatility.

From a fundamental perspective, GEHCs reveals a market capitalization of $32.51 billion, a price-to-earnings (P/E) ratio of 14.92, and a forward P/E of 17.45, indicating a relatively reasonable valuation. The companys return on equity (RoE) stands at 25.87%, demonstrating strong profitability.

Forecasting GEHCs future performance, we can anticipate a potential short-term uptrend given its current price above the 20-day SMA. However, the stock may face resistance around the 50-day SMA of $69.95, which it has recently surpassed. In the longer term, GEHCs valuation and profitability metrics suggest a stable outlook, potentially driving the stock price towards the $80-$90 range, assuming the company continues to deliver strong financial performance and innovate within the healthcare technology space.